Products Flashcards

1
Q

Define Massive transfusion protocol

A

Replacement of >1 blood volume in 24 hours
>50% of blood volume in 4 hours
In children tranfusion of >40ml/kg (blood volume in children 1 month old is approximately 80 ml/kg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Discuss goals of MPT

A

Temperuture >35

Acid base status
-Ph >7.2
-Base excess < 6
lactate <4 mmol/l

Clotting 
-Ionised calcium >1.1mmol 
-PLatelets >50
Ot/APTT <1.5 of normal 
-INR <1.5
-Fibrinogen >1.0 g/L
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Discuss risk and complications with large volume resuscitation with blood products

A
  • Volume overload
  • Over transfusion
  • Hypothermia
  • Dilutional coaguloapthy of clotting factors and platelts
  • Transfusion related acute ung injury
  • excessive citrate causing metbaolic alkalosis and hypocalcamiea
  • Hyperkalaemia
  • disease transmission

If using unmatched

  • difficulty with cross matching future blood products
  • difficulty with matching solid organs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Discuss the physioogical affect of giving PRBC

A
Electrolyte load 
NA- +15mmol 
K+2mool 
Cl- 15mmol 
Hco3 1mmol 
Lactate 0.9 mmol 

Citrate load can also lower ionised calcium level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Discuss TACO

A

Transfusion associated circulatory overload
Defined as onset or exacerbation of three or more of the following within 12 hours of the end of a tranfusion wihtout another explanation
-respiratory distress (acute or worsening)
-Evidence of pulmonary oedema on examination or radiographs
-elevated BNP
-Other unexplained CVS changes

Treatment is similar to fluid overload from any other cause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Discuss definitions of TRALI

A

Type 1 - no risk factors for ARDS and all the following are met
#a)
-acute onset
-hypoxemia (pao2/fio2 <300mmHg or spo2 <90% RA)
-Clear evidence of bilateral pulmonary oedema on imaging
-no evidence of LAH or if LAH is present it judged to not be the main contribute to the hypoxemia
#b: onset during or within 6 hours of transfusion
#c: no temporal rlationship to an alternative risk factor for ARDS

Type 2: risk factors for ARDS are present or mild ARDS at baseline, but with respiratory status deterioation that is judged to be due to transfusion based on both of the followin

1) findings as describeds in categories a and b of TRALI type 1
2) stable resp status in the 12 hours before transfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Discuss risk factors for development of TRALI

A

Recipient risk factors

  • liver transplantation surgery
  • chronic alcohol abuse
  • shock
  • higher peak ariway pressure while being mechanically ventilated
  • current smoker
  • higher interleukin 8 levels
  • positive fluid balance

Blood componenet

  • Donor sex (Female and increased parity)
  • high plasma volume blood products (whole blood, plasma, apheresis platelet concentrate)

Rd cell storage duration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Discuss pathogenesis of TRALI

A

Two hit mechanism

First hit involves neutrophil sequestration and priming in the lung microvasculature due to recipient factors such as endothelial injury. Priming refers to shifting of neutrophils to a state where they will respond to an otherwise innocuous or weak signal.

Second hit activation of recipient neutrophils by a factor in the blood product. Activation is associated with the release from neutrophils of cytokines reactive oxygen species oxidases and proteases taht damage the pulmonary capillary endothelium. This damage cause not hydrostatic pulmonary oedema.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Discuss management of TRALI

A

If TRALI is suspected the transfusion should be ceased and blood bank alerted to iniate and evaluation for a transfusion reaction. This is important for the protection of future recipients as well as for TRALI lab testing and work up

Otherwise treatment is the same as for ARDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Discuss acute transfusion realted haemolytic reactions

A

occurs during the tranfusion or with the first 24 hours after the tranfusion.

ABO associated AHTRs often occur during the early minutes of the transfusion although they may not be immediately appreciated

Patient develop chills, fever, hypotension, haemoglobinuria, renal failure, back pain or signs of DIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Discuss IX of acute transfusion related haemolytic reactions

A

Blood should be ideally drawn from the contralateral side.

  • Repeat ABO compatibility screen
  • Additional antibody studies if ABO incompatibility is excloded
  • repeat Crossmatch wiht pre and post tranfusion specimens
  • Direct COombs testing which may be positve in AHR but may by negative in ABO incompatilibility if haemolysis is so severe taht all RBCs with antibody on the surface have been lysed.
  • Haemolysis screen -LDH, conjugated and unconjugated biliruibin, haptoglobin

test for DIC

  • PT, APTT, INR all prolonged
  • Low fibrinogen
  • low platetlets
  • Low fibrinogen
  • high fibrin degradation products (FDP/D-dimer)

Monitor electrolytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Discuss management of acute transfusion related haemolytic reaction

A

Stop tranfusion
establish IV
Confirm correct product for patient
Assess patient for fever, CVS status, resp status, urticaria/angiooedema

If the intiial bedside evaluation is cconsistent with intravascular haemolysis normal saline should be infused immediatly to reduce the risks of hypotension and renal injury. -infuse at rates of 100-200ml/hr aiming for 1ml/kg/hr urine output

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Discuss febrile nonhaemolytic reactions

A

The most common of all transfusion reactions
They occur in approxaimtly 0.1-1% of all tranfusions

RIsk factors include

  • age more common in children than adults
  • product:-more likley with cellular products such as platelets or PRBC
  • Leykoreduction rends FNHTRS much less likley

FNHTR occur wihtin 1-6 hours after initiation of a transfusion- these include

  • fever
  • rigors
  • mild dyspnoea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

DIscuss management of febrile nonhaemolytic reactions

A

FNHRTS are benign causing no lasting sequalae but they are uncomfortable and sometimes frightening tio the patient. Management is typicllay as follows

  • stop infusion
  • admin antipyretics
  • evaluate for other cuases of fever inclduing more serious transfusion reactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List other types of transfusion reactions

A

Urticarial transfusion reaction - urticaria with nils otehr system involvment

IgA anaphylactic transfusion reaction. Anaphylactic reation may occur in IgA defiecient individuals who produce anti-IgA antibodies that react with IgA in the transfused product leading to anaphylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Discuss FFP

A

FFP contains all of the clotting factors, fibrinogen, plasma proteins, electrolytes, physiolgocial anticoagulants ([protein C, protein S, antithrombin, tissue factor pathway inhibitor)

17
Q

Discuss prothombinex

A

Contains factors 2, 9 and 10

dose of 25-50 IU/Kg

18
Q

Briefly discuss how ROTEM is perfromed

A

Sample of whole blood is placed in contact with a rotating pin. As the pin rotates a clot is formed which causes impairement to the rotation. This forces are read by the machine to output a tegogram.

19
Q

Discuss clotting time and causes of prolongation

A

The time from when the test first started until the temogram reaches 2mm

Prolonged

  • low fibrinogen- most common
  • low clotting factors
  • anticoagulation such as heparin
20
Q

Discuss tegogram amplitude

A

Amplitude is the clot strength
-formed by fibrinogen or platlets if low in amplitude issue with one or the iother

Measured at different time spots

  • MCF - maximal clot firmness - -30-40 minutes
  • A5 - clot firmness at 5 minutes-
21
Q

Discuss lysis times

A

Degree of loss of clot strength

can be measured at 30minute - LI30 or at maximum lysis

22
Q

Discuss Extem

A

Basic screening test - to test overall clotting profile

1st step is clotting time if low

  • low fibrinogen
  • coag factors or heparin

2nd step is A5/10/MCF

  • platelets
  • fibrinogen

3rd step is looking at maximal fibrinolysis

23
Q

Discuss Fibtem

A

Fibtem is Extem + antiplatelet agent
This allows evaluation of fibrinogen contribution to clot strenght – which is the most common reason for poor clotting

Amplitude at A5, A10 and MCF can be used

Low fibtem
-consumption
hyperfibrinolysis

24
Q

Discuss limitations of ROTEM

A

Difficult to directly assess antiplatelet drugs
Von-willibrands diseasse
?NOACs and Warfarin

25
Q

Discuss Algorithm for ROTEM interpretations

A

Treated sequentially

Hyperfibrinolysis - TXA -universal in bleeding

Fibrinogen -
-Fibtem A5 <10 indicates need for cyro or fibrinogen conentrate - aiming for Fibtem >12
-

Platelets
amplitude in the Extem
-Extem A5 <35
-Fibtem A5 >10

Clotting factors

  • Extem CT 80-140s and Fibtem A5 <10mm –> low fibrinogen
  • Extem CT >80 but Fibtem A5 > 10 –> low coag
  • Extem CT >149 and Fibtem A5 <10 - low fib and low coag
26
Q

Discuss fib concentrate

A

Powder with a 5year shelf life
Point of care (ED, ICU, theatre)
Does not require cross matching

27
Q

Discuss interpretation of TEG

A

1) clot initiation
A) R-time - time from initiation to first measurable clot
-Normal about 5-10 minutes
-Affected by clotting factors and anticoagulants
-to fix this need FFB and rev anticoagulation

2) Clot Strength 
K (kinetics) -- amount of time until 20mm of clot strength 
-dependent on fibrinogen 
-usually about 1-3 minutes 
-give cryo if prolonged 

Alpha angle

  • rate of clot formation
  • dependent on fibrinogen
  • 50-70 degrees
  • if reduced give cryo

MA - maximal ampitude

  • 55-75mm
  • dependant on platelts fibrin and factors
  • if reduced give platelets
  • also consider ddavp

3) Clot stability
- LY 30 % of clot lysis 30 minutes after MA
- fibrnolysis
- normal 0-8%
- TXA